Table 1.
Response rate in patients aged <65 and ≥65 years
| (A) Response rateITT populationn=340 | Age <65 yearsn=186 | Per cent | Age ≥65 yearsn=154 | Per cent |
|---|---|---|---|---|
| PD | 15 | 8.1 | 18 | 11.7 |
| SD | 64 | 34.4 | 51 | 33.1 |
| PR | 92 | 49.5 | 74 | 48.1 |
| CR | 15 | 8.1 | 11 | 7.1 |
| (B) Response rateNGS cohortn=182 | Age <65 yearsn=95 | Per cent | Age ≥65 yearsn=87 | Per cent |
| PD | 7 | 7.4 | 10 | 11.5 |
| SD | 34 | 35.8 | 27 | 31.0 |
| PR | 47 | 49.5 | 45 | 51.7 |
| CR | 7 | 7.4 | 5 | 5.7 |
| (C) Response rateKRAS/NRAS/BRAF/PIK3CA WTn=104 | Age <65 yearsn=53 | Per cent | Age ≥65 yearsn=51 | Per cent |
| PD | 3 | 5.7 | 6 | 11.8 |
| SD | 15 | 28.3 | 13 | 25.5 |
| PR | 30 | 56.6 | 29 | 56.9 |
| CR | 5 | 9.4 | 3 | 5.9 |
ITT population (1A), NGS cohort (1B) and KRAS, NRAS, BRAF, and PIK3CA WT patients (1C).
CR, complete response; ITT, intention to treat; NGS, next-generation sequencing; PD, progression of disease; PR, partial response; SD, stable disease; WT, wild type.